MicroRNA Profiling Applications in Cancer Diagnostics

MicroRNAs are small non-coding RNAs that modulate gene expression and whose dysregulation is strongly associated with tumour initiation, progression and metastasis. Profiling their expression patterns in tissue biopsies and biofluids has emerged as a minimally invasive strategy for cancer detection, classification and monitoring of treatment response. Advances in high-throughput sequencing, microarray technologies and sensitive electrochemical sensors have enabled comprehensive miRNA signatures to be defined for diverse malignancies. By correlating specific miRNA panels with clinicopathological parameters, researchers have developed robust biomarkers that can distinguish malignant from benign lesions, predict metastatic potential and track minimal residual disease. Integration of miRNA profiles with other molecular and imaging data offers the prospect of personalised diagnostics and dynamic real-time assessment of therapeutic efficacy.

Research from Nature Portfolio

Seminal work has elucidated how loss of particular miRNAs unleashes pro-metastatic programmes. One landmark study demonstrated that downregulation of miR-101 and miR-27a in high-grade tumours leads to derepression of key transcription factors that drive cell invasion and resistance to anti-androgen therapy. Functional experiments verified that restoring these miRNAs suppresses metastatic traits and re-sensitises resistant cells. Another influential investigation revealed that miR-141 is markedly under-expressed in cancer stem cell–enriched subpopulations, and its enforced expression curtails self-renewal, invasiveness and metastatic colonisation. Genome-wide target identification uncovered a network of Rho GTPases and stem-cell regulators directly inhibited by miR-141, establishing a multifaceted blockade to tumour progression.

MicroRNA Profiling Applications in Cancer Diagnostics publication trend

The graph below shows the total number of articles in microrna profiling applications in cancer diagnostics across all publications each year (not limited to Nature Index journals).

Technical terms

MicroRNA (miRNA): A class of ~22-nucleotide non-coding RNAs that regulate gene expression post-transcriptionally by targeting messenger RNAs for degradation or translational repression.

Liquid biopsy: A minimally invasive diagnostic approach that analyses circulating tumour-derived materials, such as cell-free DNA, RNA or exosomes, in blood, urine or other body fluids.

Exosome: A nanoscale extracellular vesicle secreted by cells, carrying proteins, lipids and nucleic acids, which reflects the molecular state of the tissue of origin.

Biomarker: A measurable molecular indicator of normal biological processes, pathogenic processes or responses to therapeutic interventions, used for diagnosis, prognosis or treatment monitoring.

References

1. Recent Electrochemical Advancements for Liquid-Biopsy Nucleic Acid Detection for Point-of-Care Prostate Cancer Diagnostics and Prognostics. Biosensors (2024).
2. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nature Communications (2017).
3. Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer. Nature Communications (2016).